Literature DB >> 14722044

The role of signal transducer and activator of transcription factors in leukemogenesis.

David W Sternberg1, D Gary Gilliland.   

Abstract

Human leukemias are frequently associated with the aberrant expression of activated fusion tyrosine kinases or activated protein tyrosine kinases carrying insertional or point mutations. The activated kinase enzymes typically phosphorylate one or more signal transducer and activator of transcription (STAT) factors, which translocate to the cell nucleus and regulate the expression of genes associated with survival and proliferation. The phosphorylation and activation of STAT family members has been described in a wide range of human leukemias. Furthermore, animal models of leukemia have demonstrated the pivotal contribution of STAT activation to leukemic pathogenesis. This review discusses evidence for the functional importance of STAT activation in the biology of leukemia and current opportunities for modulating STAT proteins in the therapy of this group of diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14722044     DOI: 10.1200/JCO.2004.10.124

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  25 in total

1.  Identification of Drosophila genes modulating Janus kinase/signal transducer and activator of transcription signal transduction.

Authors:  Tina Mukherjee; Ulrich Schäfer; Martin P Zeidler
Journal:  Genetics       Date:  2005-12-30       Impact factor: 4.562

2.  Identification of human STAT5-dependent gene regulatory elements based on interspecies homology.

Authors:  Erik A Nelson; Sarah R Walker; Wei Li; X Shirley Liu; David A Frank
Journal:  J Biol Chem       Date:  2006-07-13       Impact factor: 5.157

Review 3.  The biological functions of the versatile transcription factors STAT3 and STAT5 and new strategies for their targeted inhibition.

Authors:  Sylvane Desrivières; Christian Kunz; Itamar Barash; Vida Vafaizadeh; Corina Borghouts; Bernd Groner
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-01       Impact factor: 2.673

4.  Reducing the genotoxic potential of retroviral vectors.

Authors:  Ali Ramezani; Teresa S Hawley; Robert G Hawley
Journal:  Methods Mol Biol       Date:  2008

5.  Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.

Authors:  Zohar Sachs; Raha A Been; Krista J DeCoursin; Hanh T Nguyen; Nurul A Mohd Hassan; Klara E Noble-Orcutt; Craig E Eckfeldt; Emily J Pomeroy; Ernesto Diaz-Flores; Jennifer L Geurts; Miechaleen D Diers; Diane E Hasz; Kelly J Morgan; Margaret L MacMillan; Kevin M Shannon; David A Largaespada; Stephen M Wiesner
Journal:  Haematologica       Date:  2016-07-14       Impact factor: 9.941

6.  Comparative analyses of differentially induced T-cell receptor-mediated phosphorylation pathways in T lymphoma cells.

Authors:  Serina Ortiz; Wenhui Lee; David Smith; Stephen J Forman; Terry D Lee; Chih-Pin Liu
Journal:  Exp Biol Med (Maywood)       Date:  2010-12

7.  RA-inducible gene-I induction augments STAT1 activation to inhibit leukemia cell proliferation.

Authors:  Lin-Jia Jiang; Nan-Nan Zhang; Fei Ding; Xian-Yang Li; Lei Chen; Hong-Xin Zhang; Wu Zhang; Sai-Juan Chen; Zhu-Gang Wang; Jun-Min Li; Zhu Chen; Jiang Zhu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-11       Impact factor: 11.205

8.  Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2.

Authors:  Suhu Liu; Sarah R Walker; Erik A Nelson; Robert Cerulli; Michael Xiang; Patricia A Toniolo; Jun Qi; Richard M Stone; Martha Wadleigh; James E Bradner; David A Frank
Journal:  Mol Cancer Ther       Date:  2014-01-16       Impact factor: 6.261

Review 9.  FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.

Authors:  Zainab Jagani; Amrik Singh; Roya Khosravi-Far
Journal:  Biochim Biophys Acta       Date:  2007-10-16

10.  Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor.

Authors:  Anuradha Pradhan; Que T Lambert; Gary W Reuther
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.